ALAmy F. Lloyd

Amy F. Lloyd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy F. Lloyd has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glycogen-Dependent Metabolic Reprogramming Regulates Microglial Activation and Dysfunction in Neurodegenerative Disease

    by Hannah McAlister, Heather Merchant, Verity Mitchener, Noemi Gatto, Millie Thackray, Emily Blackburn, Libby Shackleton, Matthew S Gentry, Lorena Arancibia Carcamo, Amy F Lloyd

    Microglia are central regulators of neuroinflammation in Alzheimer’s disease (AD), yet how metabolic states modulate function remains unclear. Here we show that microglia from the APP NL-G-F mouse model revealed upregulation of glycolytic enzymes coinciding with onset of microglial activation. Surprisingly, this glycolytic shift occurred alongside reduced expression of glucose transporters, suggesting that extracellular glucose may not be the primary fuel source, implicating glycogenolysis as the potential metabolic driver. Consistent with this, significant microglial glycogen accumulation was noted in late disease, when cells exhibited features of metabolic exhaustion and functional impairment. Pharmacological inhibition of glycogenolysis blunted microglia responses to Abeta aggregates and markedly reduced Abeta uptake, confirming a functional role for glycogen metabolism in shaping microglial states. Together, these findings identify glycogen as a central regulator of microglial metabolic health and function, highlighting glycogen homeostasis as a potential therapeutic target for promoting Abeta clearance and preserving protective microglial functions in AD.

  • Open Access

    PICALM regulates a human microglial antigen presentation program in Alzheimer’s disease

    by Bart De Strooper, Sarah Borrie, Emanuela Pasciuto, Laura Van Moortel, Patrick Willems, Daan Moechars, Nicola Thrupp, Pierre Bourdely, An Snellinx, Dries T'SYen, et al.

    Microglia surrounding amyloid plaques in Alzheimer’s disease (AD) strongly upregulate HLA class II genes, but whether this transcriptional state reflects antigen presentation, and how it relates to genetic risk, remains unclear. Here we identify a broad repertoire of endogenous HLA-bound peptides in human brain extracts from individuals with and without AD. Using human microglia xenografts isolated after exposure to plaques, we show that amyloid pathology induces an HLA-expressing microglial state that presents a similarly diverse spectrum of peptide antigens. This response was accompanied by increased expression of costimulatory and coinhibitory molecules, supporting a transition towards an antigen presenting microglial state. Loss of PICALM, a major AD risk gene involved in endolysosomal trafficking, markedly amplified the microglial HLA response to amyloid pathology, and was associated with increased intracellular Aβ accumulation and modulation of immune regulatory proteins. These findings identify amyloid pathology as a driver of antigen presentation in human microglia and establish endolysosomal trafficking as a genetic regulator of this disease-associated immune state. Unexpectedly, the microglial immunopeptidome was not dominated by Aβ or tau, suggesting that amyloid plaques act less as a dominant antigenic source and more as a trigger of broader self-antigen presentation in the CNS by microglia.


  • Open Access

    Investigating how Microglia Fuel their Immune Responses in Alzheimer's Disease

    by Amy F Lloyd

    Background: Chronic inflammatory microglia is a key pathological hallmark of Alzheimer's Disease (AD) requiring high metabolic demand. Glucose is a key metabolite vital for microglia responses, and sustained hyperglycaemia is a significant risk for AD development. Understanding how microglia fuel their inflammatory responses is key to understanding how to modulate their behaviour in neurodegenerative diseases. Method: Microglia were isolated from APP‐NL‐G‐F mice at different key time points in disease progression (1, 3 and 6 months, n = 4‐6 per time point) and interrogated using mass spectrometry and proteomic analysis. Result: Proteomic analysis revealed by microglia massively upregulate their glycolysis machinery at 6 months coinciding with significant increases in inflammatory and disease associated protein expression. Interestingly, expression of glucose receptors were significantly decreased, yet increases in proteins involved in glycogen breakdown were increased. Acute (24hr) depletion of glucose in vitro also had no effect on microglia inflammatory responses to lipopolysaccharide (LPS) and glycolysis was maintained, yet longer (48hr) depletion significantly altered the microglia response. This suggests that microglia rely on glycogen reserves for metabolic flexibility and to fuel their inflammatory responses. Conclusion: Microglia utilise their internal stores of glycogen to fuel their inflammatory responses to amyloid (in vivo) and to LPS ( in vitro ). Glycogen regulated microglia responses may represent a novel therapeutic strategy for targeting microglia inflammation in neurodegenerative diseases.


  • Open Access

    Age‐Associated Inflammatory Monocytes Are Increased in Menopausal Females and Reversed by Hormone Replacement Therapy

    by R. P. H. De Maeyer, J. Sikora, O. V. Bracken, B. Shih, A. F. Lloyd, H. Peckham, K. Hollett, K. Abdelhamid, W. Cai, M. James, et al.

    Biological sex is a crucial, but poorly understood variable in age‐related susceptibility to infection. Monocytes are important immune cells responsible for initiating and resolving inflammatory responses to infection. While changes in monocyte populations result in increased susceptibility to infection, there is limited research on the impact of age and sex on human monocyte phenotype and function. The aim of this work was to dissect the impact of increasing age and biological sex on human monocyte phenotype and function. Here, we show that older females have increased inflammatory intermediate and non‐classical monocytes compared to young. These monocyte subsets were the most inflammatory ex vivo, and their frequency correlated with markers of inflammageing. Proteomic analysis of sorted monocyte populations demonstrated that the three human monocyte subsets have largely distinct phenotypes. Key age‐associated protein pathways were identified, including complement cascade and phagocytosis. We confirmed the proteomics findings, showing that circulating C3 concentrations were reduced with age in females but not males. This decrease in complement in older females resulted in reduced monocyte phagocytosis. Crucially, we demonstrate that in peri/menopausal females, hormone replacement therapy (HRT) reversed this expansion in intermediate monocytes and decreased circulating CRP as compared to age‐matched controls. Importantly, peri/menopausal females on HRT had increased C3 serum concentrations and significant improvement in monocyte phagocytosis. The data presented here indicate the importance of menopause in aging monocyte phenotype and function. These data highlight the potential use of HRT in restoring monocyte function in females during aging and potentially improving anti‐pathogen immunity.


  • Open Access

    Neonatal Microglia and Their Secretome as Mediators of Brain Repair

    by Gabriela Lyszczarz, Eydis Sigurdardottir Schioth, Anouk Benmamar-Badel, Dominika Rusin, David Ramonet, Marco Anzalone, Thalissa Caers, Lejla Vahl Becirovic, Kirstine Nolling Jensen, Sanne G.S. Verberk, et al.

    Microglia are essential regulators of myelin integrity and repair, yet their regenerative capacity declines with ageing and in neurodegenerative diseases such as multiple sclerosis (MS). Neonatal microglia retain a uniquely reparative program that may offer insight into restoring lost functions in the adult CNS. Here we show that transplantation of neonatal microglia ameliorates disability, reduces leukocyte infiltration, and promotes remyelination in both inflammatory (EAE) and non-inflammatory (cuprizone) models, and reverses cognitive decline in aged mice. These benefits persisted even when transplanted cells remained confined to the meninges and were reproduced by the neonatal microglia secretome, indicating a paracrine mechanism. Multi-omic profiling revealed that the neonatal secretome is enriched in trophic factors and membrane-building lipids compared to adult microglia, while transcriptomic analyses of treated aged brains showed reactivation of developmental repair pathways and suppression of inflammatory signatures. Together, these results demonstrate that neonatal microglia re-engage rejuvenation-like programs in the adult CNS and highlight the importance of multifactorial strategies, integrating trophic, metabolic, and immunomodulatory cues, over single-target approaches. Our findings establish early microglial programs as a paradigm for designing new regenerative therapies for CNS disorders.


  • Open Access

    A proteogenomic tool uncovers protein markers for human microglial states

    by Philip De Jager, Verena Haage, Alex Bautista, John Tuddenham, Victoria Marshe, Rebecca Chiu, Yunduo Liu, Tsering Lama, Shane Kelly, Neelang Parghi, et al.

    Human microglial heterogeneity has been largely described using transcriptomic data. Here, we introduce a microglial proteomic data resource and a Cellular Indexing of Transcriptomes and Epitopes by Sequencing panel enhanced with antibodies targeting 17 microglial cell surface proteins (mCITE-Seq). We evaluated mCITE-Seq on HMC3 microglia-like cells, induced-pluripotent stem cell-derived microglia (iMG), and freshly isolated primary human microglia. We identified novel protein microglial markers such as CD51 and relate expression of 101 cell surface proteins to transcriptional programs. This results in the identification and validation of three protein marker combinations with which to purify microglia enriched with each of 23 transcriptional programs; for example, CD49D, HLA-DR and CD32 enrich for GPNMBhigh (“disease associated”) microglia. Further, we identify and validate proteins - SIRPA, PDPN and CD162 – that differentiate microglia from infiltrating macrophages. The mCITE-Seq panel enables the transition from RNA-based classification and facilitates the functional characterization and harmonization of model systems.

  • Open Access

    A proteogenomic tool uncovers protein markers for human microglial states

    by Verena Haage, Alex R. Bautista, John Tuddenham, Victoria Marshe, Rebecca Chiu, YunDuo Liu, Tsering Lama, Shane S. Kelly, Neelang A. Parghi, Junho Park, et al.

    Human microglial heterogeneity has been largely described using transcriptomic data. Here, we introduce a microglial proteomic data resource and a Cellular Indexing of Transcriptomes and Epitopes by Sequencing panel enhanced with antibodies targeting 17 microglial cell surface proteins (mCITE-Seq). We evaluated mCITE-Seq on HMC3 microglia-like cells, induced-pluripotent stem cell-derived microglia (iMG), and freshly isolated primary human microglia. We identified novel protein microglial markers such as CD51 and relate expression of 101 cell surface proteins to transcriptional programs. This results in the identification and validation of three protein marker combinations with which to purify microglia enriched with each of 23 transcriptional programs; for example, CD49D, HLA-DR and CD32 enrich for GPNMB high (“disease associated”) microglia. Further, we identify and validate proteins - SIRPA, PDPN and CD162 – that differentiate microglia from infiltrating macrophages. The mCITE-Seq panel enables the transition from RNA-based classification and facilitates the functional characterization and harmonization of model systems.


  • Open Access

    Deep proteomic analysis of microglia reveals fundamental biological differences between model systems

    by Amy F. Lloyd, Anna Martinez-Muriana, Emma Davis, Michael J.D. Daniels, Pengfei Hou, Renzo Mancuso, Alejandro J. Brenes, Linda V. Sinclair, Ivana Geric, An Snellinx, et al.


  • Open Access

    The proteomic landscape of microglia in health and disease

    by Emma Davis, Emma Davis, Emma Davis, Amy F. Lloyd, Amy F. Lloyd, Amy F. Lloyd

    Microglia are the resident immune cells of the central nervous system (CNS) and as such play crucial roles in regulating brain homeostasis. Their presence in neurodegenerative diseases is known, with neurodegeneration-associated risk genes heavily expressed in microglia, highlighting their importance in contributing to disease pathogenesis. Transcriptomics studies have uncovered the heterogeneous landscape of microglia in health and disease, identifying important disease-associated signatures such as DAM, and insight into both the regional and temporal diversity of microglia phenotypes. Quantitative mass spectrometry methods are ever increasing in the field of neurodegeneration, utilised as ways to identify disease biomarkers and to gain deeper understanding of disease pathology. Proteins are the main mechanistic indicators of cellular function, yet discordance between transcript and proteomic findings has highlighted the need for in-depth proteomic phenotypic and functional analysis to fully understand disease kinetics at the cellular and molecular level. This review details the current progress of using proteomics to define microglia biology, the relationship between gene and protein expression in microglia, and the future of proteomics and emerging methods aiming to resolve heterogeneous cell landscapes.


  • Open Access

    Deep proteomic analysis of microglia reveals fundamental biological differences between model systems

    by Amy F Lloyd, Anna Martinez-Muriana, Emma Davis, Michael Jd Daniels, Pengfei Hou, Renzo Mancuso, Alejandro J Brenes, Ivana Geric, An Snellinx, Katleen Craessaerts, et al.

    Using high resolution quantitative mass spectrometry, we have generated the most comprehensive human and mouse microglia proteomic datasets to date, consisting of over 11,000 proteins across all six microglia groups. Microglia from different sources share a core protein signature of over 5600 proteins, yet fundamental differences are observed between species and culture conditions, indicating limitations for human disease modelling in mouse or in in vitro cultures of microglia. Mouse ex vivo microglia show important differences at the proteome level such as differential expression of inflammation and Alzheimer’s Disease associated proteins. We identify a tenfold difference in the protein content of ex vivo and in vitro cells and significant proteome differences associated with protein synthesis, metabolism, microglia marker expression and environmental sensors. Culturing microglia induces rapidly increased growth, protein content and inflammatory protein expression. These changes can be restored by engrafting in vitro cells into the brain, with xenografted hESC-derived microglia closely resembling microglia from human brain. This data provides an important resource for the field and highlights important considerations needed when using model systems to study human physiology and pathology of microglia.